Success Metrics

Active Trials

4(100%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Detailed Status

Active, not recruiting2

Recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

active_not_recruiting250%

recruiting250%

Recent Activity

4 active trials

Showing 4 of 4

recruitingphase_1

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

NCT06095089

active_not_recruitingphase_1

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

NCT04898634

recruitingphase_1

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

NCT07082920

active_not_recruitingphase_1

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

NCT04644770

Clinical Trials (4)

Showing 4 of 4 trials

NCT06095089Phase 1

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

Recruiting

NCT04898634Phase 1

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Active Not Recruiting

NCT07082920Phase 1

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

Recruiting

NCT04644770Phase 1

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Active Not Recruiting

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4